证券日报网讯2月12日，新北洋（002376）在互动平台回答投资者提问时表示，截至2026年1月底，新北 洋的股东户数为45297户。 ...

2026年1月29日，新北洋股价下跌2.01%，收盘报7.81元/股，成交额1.37亿元，主力资金净流出501.18万 元。当日换手率为2.21%，总市值约63.30亿元。今年以来股价累计上涨1.17%，但近5个交易日下跌 3.22%，显示短期波动。 以上内容基于公开资料整理，不构成投资建议。 业绩经营情况 2026年1月26日，新北洋发布业绩预告，预计2025年全年归属于上市公司股东的净利润为7000万元至 8000万元，同比增长44%至65%；扣除非经常性损益后的净利润为6300万元至7300万元，同比增长137% 至175%。同期，公司预计营业收入约为27.8亿元，同比增长约17%，主要受益于智能物流装备、专用打 印扫描产品及智能自助终端等业务的增长，以及海外市场拓展。 股票近期走势 经济观察网新北洋（002376）发布2025年业绩预告，预计净利润为7000万元至8000万元，同比增长44% 至65%，营业收入预计约27.8亿元，同比增长约17%。 ...

证券日报网讯 2月2日，新北洋在互动平台回答投资者提问时表示，截至2026年1月底，新北洋的股东户 数为45297户。 （文章来源：证券日报） ...

Performance Reports - Company Kexin New Energy (300731.SZ) expects a net profit of 30 million to 40 million yuan in 2025, representing a year-on-year growth of 73.62% to 131.49% due to the promotion of new battery applications [2] - Company AVIC Chengfei (302132.SZ) anticipates a net profit of 3.4 billion to 3.6 billion yuan in 2025, reflecting a growth of 5.47% to 11.67% compared to the previous year [2] - Company ST Jinggu (600265.SH) projects a revenue of 175 million to 205 million yuan in 2025, with a net loss of 265 million to 215 million yuan, potentially triggering delisting risk [2] - Company Yijiahe (603666.SH) expects a net loss of 35 million to 24 million yuan in 2025, an improvement from a loss of 218 million yuan in the previous year [3] - Company Guoke Micro (300672.SZ) forecasts a net loss of 180 million to 250 million yuan in 2025, a significant decline from a profit of 97.15 million yuan in the previous year [3] - Company Xinbeiyang (002376.SZ) anticipates a net profit of 70 million to 80 million yuan in 2025, a year-on-year increase of 44% to 65% driven by growth in smart logistics equipment [3] - Company Tianyue Advanced (688234.SH) expects a net loss of 185 million to 225 million yuan in 2025 due to increased costs and decreased market prices [4] - Company Jieshun Technology (002609.SZ) projects a net profit of 55 million to 75 million yuan in 2025, representing a growth of 75.23% to 138.96% [4] - Company Lante Optics (688127.SH) expects a net profit of 375 million to 400 million yuan in 2025, a growth of 70.04% to 81.38% [5] - Company Duofuduo (002407.SZ) anticipates a net profit of 200 million to 280 million yuan in 2025, recovering from a loss of 30.8 million yuan in the previous year [5] - Company Efort (688165.SH) expects a net loss of 450 million to 550 million yuan in 2025, with losses expected to widen significantly [5] - Company Pulit (002324.SZ) forecasts a net profit of 361 million to 416 million yuan in 2025, a year-on-year increase of 155.76% to 194.73% [6] - Company Jinchun Co. (300877.SZ) expects a net profit of 82 million to 88 million yuan in 2025, a growth of 165.04% to 184.43% [6] - Company Huahai Pharmaceutical (600521.SH) anticipates a net profit of 224 million to 335 million yuan in 2025, a decline of 70% to 80% [6] Orders and Investments - Company Dinglong Co. (300054.SZ) plans to acquire 70% of Shenzhen Haofei New Materials Co. for 630 million yuan, with a total valuation of 900 million yuan [7] - Company Chuanhuan Technology (300547.SZ) intends to invest approximately 1.1 billion yuan to establish a manufacturing headquarters in Anhui [7] - Company Mongcao Ecological (300355.SZ) has terminated a PPP project agreement, with a total project cost of 83.87 million yuan [7] - Company Fengfan Co. (601700.SH) plans to acquire 51% of Beijing Yanling Jiaye Intelligent Technology Co. for 383 million yuan [8] - Company Haowei Group (603501.SH) intends to invest up to 50 million USD in AI chip supplier Aixin Yuanzhi [8] - Company Chengda Bio (688739.SH) plans to establish a wholly-owned subsidiary with an investment of 1 billion yuan focused on innovative drug development [8] - Company Chengda Bio (688739.SH) is also setting up a pharmaceutical investment fund with a total scale of up to 1 billion yuan [9] - Company Efort (688165.SH) is planning to acquire shares of Shanghai Shengpu Fluid Equipment Co. through a combination of cash and stock [9] Major Shareholder Changes - Company Tongfu Microelectronics (002156.SZ) reports that its controlling shareholder has reduced its stake by 15 million shares, decreasing its holding from 19.79% to 18.80% [10] Listing on Beijing Stock Exchange - Company Xiamen Tungsten (600549.SH) announces that its subsidiary Jinlong Rare Earth is applying for public stock issuance and listing on the Beijing Stock Exchange [11]

证券日报网讯 1月26日，新北洋发布公告称，公司预计2025年1月1日至12月31日实现营业收入27.8亿 元，同比增长约17%；归属于上市公司股东的净利润盈利7000万元-8000万元，比上年同期4853.63万元 增长44%-65%。 （文章来源：证券日报） ...

人民财讯1月26日电，新北洋（002376）1月26日发布业绩预告，预计2025年归母净利7000万元—8000万 元，同比增长44%—65%。报告期内，智能物流装备收入规模增长，单件分离设备、直线分拣机等核心 设备的市场占有率优势地位不断巩固，并且在中国邮政成功打造多个总包集成大项目的标杆案例；专用 打印扫描产品收入快速增长，在海外市场与已有大客户的合作不断深化，销售规模持续扩大；智能自助 终端产品收入保持增长，智能货柜中标国内多个头部品牌商，冷藏展示柜的产销规模持续放大，智能快 递柜在海外市场的需求保持旺盛。 ...

2025年度，预计公司实现营业收入27.8亿元，同比增长约17%。预计归属于上市公司股东的净利润同比 增长44%-65%。公司继续保持良好的"出海"势头，海外市场占整体收入的比例保持相对较高水平；同 时，加快国内市场大客户和重点项目的合作落地，智能自助终端和物流分拣自动化等设备的销售规模不 断增长。 格隆汇1月26日丨新北洋(002376.SZ)公布，预计2025年归属于上市公司股东的净利润7,000万元-8,000万 元，比上年同期增长44%-65%，归属于上市公司股东扣除非经常性损益后的净利润6,300万元-7,300万 元，比上年同期增长137%-175%。 ...

南财智讯1月26日电，新北洋公告，预计2025年全年归属于上市公司股东的净利润为7000万元—8000万 元，同比预增44.00%—65.00%；预计2025年全年归属于上市公司股东的扣除非经常性损益的净利润为 6300万元—7300万元，同比预增137.00%—175.00%；主要变动原因为：2025年度，预计公司实现营业 收入27.8亿元，同比增长约17%。预计归属于上市公司股东的净利润同比增长44%—65%。主要驱动因 素包括：（一）多个业务板块收入增长明显：一是智能物流装备收入规模增长，单件分离设备、直线分 拣机等核心设备的市场占有率优势地位不断巩固，并且在中国邮政成功打造多个总包集成大项目的标杆 案例；二是专用打印扫描产品收入快速增长，在海外市场与已有大客户的合作不断深化，销售规模持续 扩大；三是智能自助终端产品收入保持增长，智能货柜中标国内多个头部品牌商，冷藏展示柜的产销规 模持续放大，智能快递柜在海外市场的需求保持旺盛。（二）国内海外市场共同发力：公司继续保持良 好的"出海"势头，海外市场占整体收入的比例保持相对较高水平；同时，加快国内市场大客户和重点项 目的合作落地，智能自助终端和物流分拣自动 ...

一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日—2025 年 12 月 31 日 2、业绩预告情况：自愿性业绩预告 | 项 目 | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净 利润 | 盈利：7,000 | 万元-8,000 | 万元 | 盈利：4,853.63 | 万元 | | | 比上年同期增长：44%-65% | | | | | | 归属于上市公司股东扣除 | 盈利：6,300 | 万元-7,300 | 万元 | 盈利：2,655.25 | 万元 | | 非经常性损益后的净利润 | 比上年同期增长：137%-175% | | | | | | 基本每股收益 | 盈利：0.0882 | 元-0.1008 | 元 | 盈利：0.0750 | 元/股 | 注：上表中数值如有尾差，为四舍五入所致。 证券代码：002376 证券简称：新北洋 公告编号：2026-001 山东新北洋信息技术股份有限公司 2025 年度业绩预增公告 本公司及董事会全体成员保证公告内容真实、准确和完整，并对公告中的虚假 ...

Core Viewpoint - The article discusses the pharmaceutical traceability code scanning all-in-one machine, highlighting its importance in ensuring drug quality and compliance with traceability regulations in the pharmaceutical industry [2][9]. Market Size and Industry Landscape - According to QYResearch, the global market for pharmaceutical traceability code scanning all-in-one machines is projected to reach USD 470 million by 2032, with a compound annual growth rate (CAGR) of 7.3% in the coming years [3]. - Major manufacturers in the global market include Soman Technology, SUPOIN, iData, Shenzhen Youbuxun Technology Co., Ltd., and others [5][6]. Industry Chain Analysis - The industry chain consists of upstream hardware component suppliers, software developers, midstream device manufacturers, and downstream pharmaceutical distributors and retail pharmacies [8]. Industry Policy Analysis - Recent regulatory policies in China and the U.S. are accelerating the adoption of traceability code scanning devices, increasing demand for compliant integrated devices [9]. Trends in Smart Functionality - The integration of advanced AI capabilities for automatic error correction and IoT-based device monitoring is enhancing the efficiency and accuracy of scanning machines [10]. - The expansion of multi-modal code recognition capabilities allows devices to read various formats, improving their utility in logistics [10]. Industry Development Opportunities - Regulatory-driven demand for compliant devices is creating a significant market opportunity, especially in underdeveloped regions [12]. - The shift towards smart upgrades is prompting existing users to replace outdated devices with advanced models [12]. - Opportunities exist to extend the application of these devices to adjacent regulatory fields, such as medical devices and health supplements [12]. Data Value Extraction and Collaborative Service Opportunities - The ability of scanning devices to collect vast amounts of drug flow data presents opportunities for collaboration with pharmaceutical companies and regulatory bodies to provide value-added data services [13]. Industry Development Challenges - The industry faces high compliance and technical barriers, requiring significant investment in R&D and certification [14]. - Small pharmaceutical entities are under financial pressure to comply with regulations, which may hinder market penetration [14]. - Data interoperability issues between different systems can weaken the effectiveness of traceability efforts [14]. After-Sales Service and Maintenance Bottlenecks - Uneven distribution of after-sales service networks can lead to delays in equipment repair, posing compliance risks [15].